1450 related articles for article (PubMed ID: 30464691)
1. Predictors of immunotherapy-induced immune-related adverse events.
Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population.
Sattar J; Kartolo A; Hopman WM; Lakoff JM; Baetz T
J Geriatr Oncol; 2019 May; 10(3):411-414. PubMed ID: 30104155
[TBL] [Abstract][Full Text] [Related]
3. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
4. Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series.
Moseley KF; Naidoo J; Bingham CO; Carducci MA; Forde PM; Gibney GT; Lipson EJ; Shah AA; Sharfman WH; Cappelli LC
J Immunother Cancer; 2018 Oct; 6(1):104. PubMed ID: 30305172
[TBL] [Abstract][Full Text] [Related]
5. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
6. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
Rogado J; Sánchez-Torres JM; Romero-Laorden N; Ballesteros AI; Pacheco-Barcia V; Ramos-Leví A; Arranz R; Lorenzo A; Gullón P; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondéjar R; Colomer R
Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533
[TBL] [Abstract][Full Text] [Related]
7. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
8. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.
Cortellini A; Chiari R; Ricciuti B; Metro G; Perrone F; Tiseo M; Bersanelli M; Bordi P; Santini D; Giusti R; Grassadonia A; Di Marino P; Tinari N; De Tursi M; Zoratto F; Veltri E; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Iacono D; Migliorino MR; Porzio G; Cannita K; Ficorella C; Buti S
Clin Lung Cancer; 2019 Jul; 20(4):237-247.e1. PubMed ID: 30885550
[TBL] [Abstract][Full Text] [Related]
9. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
10. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
11. Management of toxicities of immune checkpoint inhibitors.
Spain L; Diem S; Larkin J
Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
[TBL] [Abstract][Full Text] [Related]
12. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
Delanoy N; Michot JM; Comont T; Kramkimel N; Lazarovici J; Dupont R; Champiat S; Chahine C; Robert C; Herbaux C; Besse B; Guillemin A; Mateus C; Pautier P; Saïag P; Madonna E; Maerevoet M; Bout JC; Leduc C; Biscay P; Quere G; Nardin C; Ebbo M; Albigès L; Marret G; Levrat V; Dujon C; Vargaftig J; Laghouati S; Croisille L; Voisin AL; Godeau B; Massard C; Ribrag V; Marabelle A; Michel M; Lambotte O
Lancet Haematol; 2019 Jan; 6(1):e48-e57. PubMed ID: 30528137
[TBL] [Abstract][Full Text] [Related]
13. The impact of corticosteroid use during anti-PD1 treatment.
Pan EY; Merl MY; Lin K
J Oncol Pharm Pract; 2020 Jun; 26(4):814-822. PubMed ID: 31495293
[TBL] [Abstract][Full Text] [Related]
14. Multiple sclerosis outcomes after cancer immunotherapy.
Garcia CR; Jayswal R; Adams V; Anthony LB; Villano JL
Clin Transl Oncol; 2019 Oct; 21(10):1336-1342. PubMed ID: 30788836
[TBL] [Abstract][Full Text] [Related]
15. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.
Menzies AM; Johnson DB; Ramanujam S; Atkinson VG; Wong ANM; Park JJ; McQuade JL; Shoushtari AN; Tsai KK; Eroglu Z; Klein O; Hassel JC; Sosman JA; Guminski A; Sullivan RJ; Ribas A; Carlino MS; Davies MA; Sandhu SK; Long GV
Ann Oncol; 2017 Feb; 28(2):368-376. PubMed ID: 27687304
[TBL] [Abstract][Full Text] [Related]
16. Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events.
Wijn DH; Groeneveld GH; Vollaard AM; Muller M; Wallinga J; Gelderblom H; Smit EF
Eur J Cancer; 2018 Nov; 104():182-187. PubMed ID: 30368069
[TBL] [Abstract][Full Text] [Related]
17. Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers.
Liu RC; Consuegra G; Chou S; Fernandez Peñas P
Clin Exp Dermatol; 2019 Aug; 44(6):643-646. PubMed ID: 30618056
[TBL] [Abstract][Full Text] [Related]
18. Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study.
Presotto EM; Rastrelli G; Desideri I; Scotti V; Gunnella S; Pimpinelli N; Vaccher E; Bearz A; Di Costanzo F; Bruggia M; Mini E; Maggi M; Peri A
J Endocrinol Invest; 2020 Mar; 43(3):337-345. PubMed ID: 31542865
[TBL] [Abstract][Full Text] [Related]
19. Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.
Sukari A; Nagasaka M; Alhasan R; Patel D; Wozniak A; Ramchandren R; Vaishampayan U; Weise A; Flaherty L; Jang H; Kim S; Gadgeel S
Anticancer Res; 2019 Feb; 39(2):781-790. PubMed ID: 30711957
[TBL] [Abstract][Full Text] [Related]
20. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M
J Cancer Res Clin Oncol; 2019 Feb; 145(2):511-521. PubMed ID: 30539281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
